Amgen Venture Capital Fund Starts With $100 Mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen Ventures will focus investment in early biotech companies researching areas of "current therapeutic interest to Amgen," including oncology, metabolic disorders and inflammation.
You may also be interested in...
Amgen's $1.3 Bil. Acquisition Of Tularik Would Yield Two Late-Stage Oncologics
Tularik would broaden Amgen's oncology portfolio to small molecules with compounds for hepatocellular carcinoma, and esophageal and gastric cancers. The deal is one-tenth the size of Amgen's last acquisition – the $10 bil. Immunex purchase.
Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability
McKindler? New Pfizer CEO Echoes McKinnell’s Views On Payers, Scale
Pfizer's success will depend on its ability to negotiate the paradox of increasing demand for pharmaceuticals coupled with growing attempts to restrain costs, CEO Jeffrey Kindler said